UMass Lowell

Biotechnology Option

The Boston area is rich in biomedical, pharmaceutical and other biotech companies and organizations. UMass Lowell prepares Biotechnology Option students for careers in this area with practical, ...
VentureBeat

AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes

AVM Biotechnology, LLC, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business ...
ksn.com

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on ...

SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...
Business Wire

Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...
Business Wire

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively As previously ...
Benzinga.com

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls

Unity Biotechnology, Inc. (NASDAQ:UBX) stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients ...